Suchergebnisse - "Nicholas, Jacqueline"

PubPharm (4)

1

Benefits of early treatment with natalizumab : a real-world study

enthalten in: Multiple sclerosis and related disorders | 2022

von Ontaneda, D. | Mowry, E. | Newsome, S. | +9

2

Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA) : a randomised, controlled, open-label, phase 3b trial

enthalten in: The Lancet. Neurology | 2022

von Foley, J. | Defer, G. | Ryerson, L. | +98

CommentIn: Lancet Neurol. 2022 Jul;21(7):579-581. - PMID 35483388

3

Real-world cost of treatment for multiple sclerosis patients initiating and receiving infused disease-modifying therapies per recommended label in the United States

enthalten in: Journal of medical economics | 2020

von Nicholas, J. | Halpern, R. | Ziehn, M. | +3

4

Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab

enthalten in: JAMA neurology | 2013

von Boster, A. | Nicholas, J. | Topalli, I. | +6

1
[1]